Leo Pharma Pursues Deals, New Drugs, To Compete With Big Pharma
Executive Summary
Denmark’s specialty dermatology company, Leo Pharma, has globalized its infrastructure and is now investing in its internally and externally sourced product pipeline to help it compete with big pharma companies keen to move into the therapeutic area.
You may also be interested in...
Reducing The Pain Of Skin R&D: Almirall And Leo Collaborate
Two European companies with portfolios in skin conditions have taken their first collaborative steps, researching non-painful skin sampling.
Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.
Sun Builds On Psoriasis Data But Can It Hold In Crowded Space?
Sun Pharma’s executive vice president, biologics and dermatology, Jesper Ostergaard Jensen, elaborates on some aspects of the recent encouraging data around the company’s late stage psoriasis asset, tildrakizumab. Jensen also tells Scrip that the firm is upbeat about its acne and photodynamic therapy products in the US.